findmyKOL
Clinical trialNCT03471624CompletedPhase 4Interventional

Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)

SponsorStanford UniversityEnrollment270Hepatitis B, Chronic
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Primary Objective: To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Japan
  • Kyushu University Hospital

    Fukuoka, Japan

  • Nagoya City University

    Nagoya, Japan

  • Osaka City University

    Osaka, Japan

  • Saga University Hospital

    Saga, Japan

South Korea
  • Hanyang University Seoul Hospital

    Seoul, South Korea

  • Nowon Eulji Medical Center, Eulji University College of Medicine,

    Seoul, South Korea

  • Sanggye Paik Hospital, Inje University College of Medicine

    Seoul, South Korea

Taiwan
  • E-Da Hospital

    Kaohsiung City, Taiwan

  • Kaohsiung Medical University Hospital

    Kaohsiung City, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

United States
  • Stanford University Medical Center

    Palo Alto, California, United States

  • San Jose Gastroenterology

    San Jose, California, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Tenofovir alafenamide →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 May 2018
Primary completion
19 Apr 2022
Completion
19 Apr 2022
Last update posted
18 Nov 2023
Registered enrollment
270
Registry id
NCT03471624
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.